SRPT Q4 2023 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$397M+53.5% YoY

Gross Profit

$353M88.9% margin

Operating Income

$25M6.2% margin

Net Income

$46M11.5% margin

EPS (Diluted)

$0.43

QoQ Revenue Growth

+19.6%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$74M

Stock-Based Comp.

$46M

Balance Sheet

Total Assets

$3.3B

Total Liabilities

$2.4B

Stockholders' Equity

$859M

Cash & Equivalents

$428M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$397M	$258M	+53.5%
Gross Profit	$353M	$228M	+54.9%
Operating Income	$25M	-$107M	+123.0%
Net Income	$46M	-$109M	+141.8%

Geographic Segments

UNITED STATES

$195M65%

Rest of World

$104M35%